156 related articles for article (PubMed ID: 10429977)
1. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
Abdel-Wahab M; El-Shennawy F; Agha S; Ragab E; Fathi O; Sultan A; Elghawalby N; Ezzat F
Hepatogastroenterology; 1999 May; 46 Suppl 1():1293-6. PubMed ID: 10429977
[TBL] [Abstract][Full Text] [Related]
2. Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters.
Boura P; Kountouras J; Lygidakis NJ; Safioleas M; Aphinives P
Hepatogastroenterology; 1999; 46(26):799-803. PubMed ID: 10370616
[TBL] [Abstract][Full Text] [Related]
3. Combined immunopharmaceutical therapy of patients with unresectable pancreatic carcinoma.
Lygidakis NJ; Ziras FA; Kyparidou E; Parissis J; Papadopoulou P; Venetsanou B
Hepatogastroenterology; 1995; 42(6):1039-52. PubMed ID: 8847017
[TBL] [Abstract][Full Text] [Related]
4. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
5. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
[TBL] [Abstract][Full Text] [Related]
6. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
7. A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization.
Homma H; Doi T; Mezawa S; Takada K; Kukitsu T; Oku T; Akiyama T; Kusakabe T; Miyanishi K; Niitsu Y
Cancer; 2000 Jul; 89(2):303-13. PubMed ID: 10918160
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy following pancreatic resection for pancreatic duct carcinoma: a prospective randomized study.
Lygidakis NJ; Stringaris K
Hepatogastroenterology; 1996; 43(9):671-80. PubMed ID: 8799414
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.
Tímár J; Ladányi A; Forster-Horváth C; Lukits J; Döme B; Remenár E; Godény M; Kásler M; Bencsik B; Répássy G; Szabó G; Velich N; Suba Z; Elo J; Balatoni Z; Pócza K; Zemplén B; Chretien P; Talor E
J Clin Oncol; 2005 May; 23(15):3421-32. PubMed ID: 15908653
[TBL] [Abstract][Full Text] [Related]
12. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
13. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
14. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
15. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
16. Free-from-progression period and overall short preoperative immunotherapy with IL-2 increases the survival of pancreatic cancer patients treated with macroscopically radical surgery.
Caprotti R; Brivio F; Fumagalli L; Nobili C; Degrate L; Lissoni P; Parolini D; Messina G; Colciago M; Scotti M; Uggeri F
Anticancer Res; 2008; 28(3B):1951-4. PubMed ID: 18630487
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of radiation therapy combined with intra-arterial infusion chemotherapy in patients with non-resectable pancreatic cancer].
Ohigashi H; Ishikawa O; Nakamori S; Masutani S; Sasaki Y; Kameyama M; Hiratsuka M; Kabuto T; Furukawa H; Imaoka S
Gan To Kagaku Ryoho; 1992 Aug; 19(10 Suppl):1682-4. PubMed ID: 1530331
[TBL] [Abstract][Full Text] [Related]
18. Intrasplenic immunostimulation in malignancies fact or fiction? Present and future.
Lygidakis NJ; Spenzouris N; Dedemadi G; Kyriakou A; Theodorakopoulos M
Hepatogastroenterology; 1998; 45(20):404-10. PubMed ID: 9638414
[TBL] [Abstract][Full Text] [Related]
19. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
20. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study.
Morganti AG; Valentini V; Macchia G; Mattiucci GC; Costamagna G; Deodato F; Smaniotto D; Luzi S; Balducci M; Barbi S; Perri V; Trodella L; Cellini N
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1454-60. PubMed ID: 15275732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
